Following on from information provided to NICE by the company in September 2016, the appraisal of Cediranib for treating relapsed, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 790 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in September 2016, the appraisal of Cediranib for treating relapsed, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 05 October 2016 | The Appraisal Committee was due to meet on 15 November 2016 to discuss cediranib for treating relapsed, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer. The company has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled. |
| 21 September 2016 | Suspended. The company Astrazeneca has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled. |
| 24 June 2016 | Invitation to participate |
| 27 November 2015 | Draft scope documents |
| 04 November 2015 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual